Fresh off FDA approval, GlaxoSmithKline's Shingrix gets CDC panel vote over Merck shot

25th October 2017 Uncategorised 0

In a significant lift for GlaxoSmithKline’s new shingles vaccine, the CDC committee in charge of vaccination policy in the U.S. endorsed Shingrix over the older shot, Merck’s Zostavax. If confirmed, the decision will give the newly approved GSK product a long launch runway, as tens of millions U.S. adults would be encouraged to get the two-dose option.

More: Fresh off FDA approval, GlaxoSmithKline's Shingrix gets CDC panel vote over Merck shot
Source: fierce